LIMD1-AS1 promotes the progression of prostate cancer and affects the function of prostate cancer cells by down-regulating miR-29c-3p
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-06046-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Yongsheng Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urinary Surgery, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangdong, 511300, China. Hauptthemen laut MEDLINE: MicroRNAs, Prostatic Neoplasms, Disease Progression, Cell Proliferation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: Prostate cancer (PCa) is a prevalent and lethal malignancy affecting males, with a considerable proportion of patients experiencing poor survival outcomes. The regulatory role of LIMD1-AS1 in the initiation and progression of PCa is emerging as a significant factor, however, the precise mechanisms governing its influence are yet to be fully elucidated. METHODS: qRT-PCR was employed to assess the expression of LIMD1-AS1 and miR-29c-3p. The Cell Counting Kit-8 (CCK-8) was used to assess cell proliferation in PCa cells. Apoptosis rates were determined using flow cytometry. Cell migration and invasion were evaluated using the transwell assay. The targeted relationship of LIMD1-AS1 and miR-29c-3p was confirmed through dual-luciferase reporter gene analysis. RESULTS: Increased expression of LIMD1-AS1 and decreased expression of miR-29c-3p were observed in both tumor tissues and serum from PCa patients. LIMD1-AS1 exhibited diagnostic and prognostic significance in PCa patients. Functionally, LIMD1-AS1 modulated the expression of miR-29c-3p to potentiate the proliferative, migratory, and invasive capabilities of PCa cells while concurrently inhibiting apoptosis. CONCLUSION: LncRNA LIMD1-AS1 promotes the advancement of PCa by regulating miR-29c-3p, indicating that LIMD1-AS1/miR-29c-3p axis could serve as potential therapeutic targets for the therapeutic intervention of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urinary Surgery, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangdong, 511300, China.
- Department of Pharmacology, Wuhan University TaiKang Medical School (School of Basic Medical Sciences), Hubei, 430071, China.
- Department of Urology Surgery, Jiaozhou Central Hospital of Qingdao, Shandong, 266300, China.
- Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan Second Road, Guangzhou City, Guangdong Province, 510080, China. Wangchanggz@163.com.
- Department of Trauma and Joint Surgery, The Fourth Affiliated Hospital of Guangzhou Medical University, No. 1, Guangming East Road, Zengcheng District, Guangzhou City, Guangdong Province, 511300, China. Xujinhuanggz@163…
Zitieren
APA
Yu, Y., He, N., Song, Z., Wang, C., & Xu, J. (2024). LIMD1-AS1 promotes the progression of prostate cancer and affects the function of prostate cancer cells by down-regulating miR-29c-3p. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-06046-0
Vancouver
Yu Y, He N, Song Z, Wang C, Xu J. LIMD1-AS1 promotes the progression of prostate cancer and affects the function of prostate cancer cells by down-regulating miR-29c-3p. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-06046-0
BibTeX
@article{Yu2024,
author = {Yu, Yongsheng and He, Nan and Song, Zhaolu and Wang, Chang and Xu, Jinhuang},
title = {LIMD1-AS1 promotes the progression of prostate cancer and affects the function of prostate cancer cells by down-regulating miR-29c-3p},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-06046-0}
}
EUVIMED